CD4 and non-small cell lung carcinoma: Meta-analysis indicated that there was a statistically significant difference between two groups for CD3+ [WMD = 15.09, 95% CI (11.13, 19.05), P < 0.00001], CD4+ [WMD = 10.25, 95% CI (7.31, 13.20), P < 0.00001], and CD4+/CD8+ [WMD = 0.44, 95% CI (0.25, 0.63), P < 0.00001], which explained that SFI combined with chemotherapy could obviously enhance the immune function of NSCLC patients.